Here is how Philip Morris (PM) and Vital Farms (VITL) have performed compared to their sector so far this year.
While the top- and bottom-line numbers for Philip Morris (PM) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Philip Morris (PM) came out with quarterly earnings of $1.59 per share, beating the Zacks Consensus Estimate of $1.55 per share. This compares to earnings of $1.60 per share a year ago.
PM's smokeable portfolio is less susceptible to the trends underlying the cigarette volume declines. The Company delivered impressive growth of its smoke-free portfolio and is set to reach its 2030 Vision. I don't see a strong upside through multiple appreciation in the short term. However, PM's long-term owners are highly likely to benefit greatly.
Philip Morris (NYSE: PM) is scheduled to report its Q2 2024 results on Tuesday, July 23. We expect the company to post revenue and earnings marginally below the consensus estimates.
No less than six health and consumer groups are teaming up to oppose the planned IQOS rollout in this country. They are lobbying the Food and Drug Administration to keep the product off U.S. store shelves.
Philip Morris' (PM) Q2 results are likely to reflect gains from smoke-free products like IQOS and ZYN, along with efficient pricing amid elevated costs.
Philip Morris International Inc. (NYSE:PM) stock was last seen up 1.5% to trade at $107.66, ahead of the tobacco giant's second-quarter earnings report, due out before the open on Tuesday, July 26.
Philip Morris' (PM) announcement of a $600 million investment to establish a manufacturing facility in Aurora, CO, presents several strategic advantages and promising growth opportunities.
The nicotine pouches have spiked in popularity among young adults and teens.
Philip Morris (PM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health campaigners have written to U.S. regulators accusing Philip Morris International of misrepresenting past regulatory decisions, seeking to disrupt the launch of its flagship heated tobacco device IQOS in the United States.